screenpoint-medical.com

What It Is

Transpara Breast AI is an AI tool from ScreenPoint Medical for breast imaging screening, positioned as a “second pair of eyes” for assisted detection and triage. It supports both 2D/FFDM and 3D/DBT mammography, is FDA cleared and CE marked, and has been deployed in more than 30 countries across 1,000+ institutions. According to the official website, it has processed over 11 million exams.

Core Capabilities and Clinical Evidence

The core product is Transpara Detection, which uses deep learning algorithms to help radiologists find more breast cancers, while also supporting high-risk prioritization and low-risk triage through risk scoring. Its evidence base is relatively strong: the official website states that it has a large number of independent peer-reviewed publications and has been involved in three randomized controlled trials: MASAI in Sweden, PRISM in the United States, and AIMS in Norway. The MASAI study showed that after incorporating Transpara, the cancer detection rate increased by 29% and reading workload decreased by 44%, with the same specificity, improved sensitivity, and a non-inferior interval cancer rate reported.

Integration, Ease of Use, and Workflow

Transpara emphasizes that it is vendor agnostic, compatible with major mammography systems, and integrates with all major PACS vendors and hanging protocols. It supports different reading environments, including single reading and double reading, making it suitable for institutions with high screening volumes, shortages of radiologists, or a need for risk-stratified screening. Physician feedback frequently mentions that it helps improve confidence, prioritize high-risk cases, and enhance workflow.

Pricing and Access in China

The official website does not disclose public pricing, plans, free quotas, or trials; it only offers demo booking and personalized consultation, suggesting institution-level customized procurement. Payment methods are also not specified. Information about access from China, a Chinese interface, Chinese-language support, or local medical device compliance is not mentioned in the available materials, so its feasibility for deployment in China remains unknown. Actual procurement would still require assessment of network access, cross-border data transfer, in-hospital PACS integration, regulatory registration, and local clinical validation. As alternatives, institutions should compare locally compliant breast imaging AI products or existing hospital imaging platforms.

Pros, Cons, and Who It’s For

Its strengths include a relatively solid clinical evidence base, support for both 2D and 3D imaging, clear integration capabilities, and extensive international deployment experience. Its drawbacks are opaque pricing, limited public detail on privacy and data processing, and no visible support for Chinese language or the China market in public materials. It is better suited to large hospitals, regional screening programs, and breast imaging centers with PACS integration capabilities, rather than individual users or small-scale settings that lack medical AI procurement and compliance capacity.